Mutations in the RAS-RAF-MEK-ERK pathway seem to preferably occur after treatment with type I FLT3 inhibitors, as revealed by an NGS-based analysis of 67 FLT3-mutated AML cases with secondary FLT3 inhibitor resistance performed by Alotaibi et al. [31]. Here, FLT3 is linked to acute myeloid leukemia.